Giuseppe Giaccone

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors
    J Voortman
    National Cancer Institute, Building 10 Magnuson CC, Room 12N226, 10 Center Drive, Bethesda, MD 20892, USA
    Curr Pharm Des 19:833-40. 2013
  2. pmc The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone
    Sid P Kerkar
    Surgery Branch, CCR, NCI, Bethesda, MD, USA
    Trials 10:121. 2009
  3. pmc The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells
    Jens Voortman
    Department of Medical Oncology, VU University Medical Center, 1081HV Amsterdam, The Netherlands
    Mol Cancer 6:73. 2007
  4. pmc Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer
    Hester van Cruijsen
    Department of Medical Oncology, VU University Medical Center, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    BMC Cancer 9:180. 2009
  5. pmc Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors
    Giuseppe Giaccone
    Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Clin Oncol 29:2052-9. 2011
  6. pmc Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors
    Giuseppe Giaccone
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1906, United States
    Cancer Treat Rev 37:456-64. 2011
  7. doi request reprint Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy
    Giuseppe Giaccone
    Free University Medical Center, Amsterdam, The Netherlands
    J Cancer Res Clin Oncol 135:467-76. 2009
  8. doi request reprint Src as a potential therapeutic target in non-small-cell lung cancer
    G Giaccone
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1906, USA
    Ann Oncol 19:1219-23. 2008
  9. doi request reprint Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer
    Giuseppe Giaccone
    Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 27:4481-6. 2009
  10. pmc Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer
    Jeremy Force
    Medical Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD, USA
    J Thorac Oncol 6:1267-73. 2011

Detail Information

Publications131 found, 100 shown here

  1. ncbi request reprint Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors
    J Voortman
    National Cancer Institute, Building 10 Magnuson CC, Room 12N226, 10 Center Drive, Bethesda, MD 20892, USA
    Curr Pharm Des 19:833-40. 2013
    ..We evaluated the mutation status of c-Met in small cell lung cancer (SCLC) and neuroendocrine tumors (NET), for which relatively limited therapeutic targets have been explored...
  2. pmc The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone
    Sid P Kerkar
    Surgery Branch, CCR, NCI, Bethesda, MD, USA
    Trials 10:121. 2009
    ..Several case reports and small studies have documented evidence of long-term survival in select individuals who undergo CHPP for MGC...
  3. pmc The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells
    Jens Voortman
    Department of Medical Oncology, VU University Medical Center, 1081HV Amsterdam, The Netherlands
    Mol Cancer 6:73. 2007
    ..Further studies in NSCLC are warranted to elucidate underlying mechanisms...
  4. pmc Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer
    Hester van Cruijsen
    Department of Medical Oncology, VU University Medical Center, Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    BMC Cancer 9:180. 2009
    ....
  5. pmc Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors
    Giuseppe Giaccone
    Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Clin Oncol 29:2052-9. 2011
    ..Antitumor activity of histone deacetylase (HDAC) inhibitors in this disease has been documented, including one patient with thymoma treated with the pan-HDAC inhibitor belinostat...
  6. pmc Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors
    Giuseppe Giaccone
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1906, United States
    Cancer Treat Rev 37:456-64. 2011
    ..As drug resistance appears to be pleomorphic, combinations of drugs or drugs with multiple targets may be more effective in circumventing resistance...
  7. doi request reprint Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy
    Giuseppe Giaccone
    Free University Medical Center, Amsterdam, The Netherlands
    J Cancer Res Clin Oncol 135:467-76. 2009
    ..Epidermal growth factor receptor (EGFR) staining was assessed retrospectively in relation to survival response to gefitinib in combination with chemotherapy...
  8. doi request reprint Src as a potential therapeutic target in non-small-cell lung cancer
    G Giaccone
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 1906, USA
    Ann Oncol 19:1219-23. 2008
    ..Preliminary preclinical data and pharmacodynamic data suggest that Src inhibition is a viable therapeutic option in the treatment of advanced NSCLC...
  9. doi request reprint Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer
    Giuseppe Giaccone
    Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 27:4481-6. 2009
    ..To evaluate the antitumor activity and safety of YM155, a novel, small-molecule suppressor of survivin, as single-agent therapy in patients with previously treated, advanced non-small-cell lung cancer (NSCLC)...
  10. pmc Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer
    Jeremy Force
    Medical Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD, USA
    J Thorac Oncol 6:1267-73. 2011
    ..In this study, we aimed to determine the effectiveness of volumetric response evaluation criteria in solid tumors (volumetrics) for evaluating response in patients with thymic malignancies treated on a phase II study of belinostat...
  11. doi request reprint A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors
    Arun Rajan
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 18:2344-51. 2012
    ..To determine the safety and tolerability of olaparib with cisplatin and gemcitabine, establish the maximum tolerated dose (MTD), and evaluate the pharmacodynamic and pharmacokinetic profile of the combination...
  12. pmc Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib
    Ronan J Kelly
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1457, USA
    Clin Cancer Res 17:1190-9. 2011
    ..Sorafenib, a multikinase inhibitor targeting Raf and VEGFR, has shown activity in unselected patients with non-small-cell lung cancer (NSCLC). At present there are no validated biomarkers indicative of sorafenib activity...
  13. doi request reprint Expression and mutational status of c-kit in thymic epithelial tumors
    Iacopo Petrini
    Department of Medical Oncology and Hematology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Thorac Oncol 5:1447-53. 2010
    ..We studied expression of c-kit in a large retrospective series of thymic epithelial malignancies and sequenced the whole gene in a subset of patients...
  14. pmc Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target
    Marielle I Gallegos Ruiz
    Department of Medical Oncology, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands
    PLoS ONE 3:e0001722. 2008
    ..Understanding the molecular events in non-small cell lung cancer (NSCLC) is essential to improve early diagnosis and treatment for this disease...
  15. doi request reprint Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia
    Cody J Peer
    Clinical Pharmacology Program, Pharmacology and Experimental Therapeutics Section, Molecular Pharmacology Section, Biostatistics and Data Management Branch, Medical Oncology Branch, and HIV AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 18:2099-107. 2012
    ..We hypothesized that sorafenib inhibits UGT1A1 and individuals carrying UGT1A1*28 and/or UGT1A9 variants experience greater sorafenib exposure and greater increase in sorafenib-induced plasma bilirubin concentration...
  16. pmc Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors
    Iacopo Petrini
    Medical Oncology Branch Genetics Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 19:1960-71. 2013
    ..To determine whether the deregulation of genes relevant for normal thymus development can contribute to the biology of thymic epithelial tumors (TET)...
  17. pmc Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer
    Jih Hsiang Lee
    Medical Oncology Branch, Genetic Branch, and Biostatistics and Data Management Section, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 18:524-33. 2012
    ..Pancreatic cancer is the fourth leading cause of cancer-related death, and studies on the clinical relevance of its genomic imbalances are warranted...
  18. pmc MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma
    Johannes Voortman
    Medical Oncology Branch and Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland 20892 1906, USA
    Cancer Res 70:8288-98. 2010
    ....
  19. ncbi request reprint A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors
    Jens Voortman
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 13:3642-51. 2007
    ..To establish maximum tolerated dose (MTD) and tolerability of two schedules of bortezomib in combination with cisplatin and gemcitabine as first-line treatment of patients with advanced solid tumors...
  20. pmc Population pharmacokinetic analysis of sorafenib in patients with solid tumours
    Lokesh Jain
    Clinical Pharmacology Program Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Br J Clin Pharmacol 72:294-305. 2011
    ..The pharmacokinetics (PK) of sorafenib are highly variable between subjects. Sorafenib exposure increases less than dose proportionally (likely due to limited solubility). Sorafenib undergoes enterohepatic recycling (EHC)...
  21. ncbi request reprint The immunoregulatory role of CD1d-restricted natural killer T cells in disease
    Hans J J van der Vliet
    The Departments of Pathology, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands
    Clin Immunol 112:8-23. 2004
    ..Here, we review the immunoregulatory role of NKT cells in disease and discuss NKT cell based immunotherapeutic strategies...
  22. doi request reprint Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas
    Giuseppe Giaccone
    Department of Medical Oncology, VU Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 4:1270-3. 2009
    ..Imatinib has no major activity in this rare tumor. Given the small number of patients treated in this study, selection based on presence of c-KIT mutations might be warranted...
  23. pmc Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer
    Jin Hyeok Hwang
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e10630. 2010
    ..The aim of the present study was to evaluate whether expression of novel candidate biomarkers, including microRNAs, can predict clinical outcome in PDAC patients treated with adjuvant therapy...
  24. pmc Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
    Lokesh Jain
    Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Exp Clin Cancer Res 29:95. 2010
    ..We hypothesized that these toxicities would correspond to favorable outcome in these drugs, that HT and HFSR would coincide, and that VEGFR2 genotypic variation would be related to toxicity and clinical outcomes...
  25. ncbi request reprint Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 12:6049-55. 2006
    ..Erlotinib has proven activity in pretreated patients with advanced non-small cell lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC and assessed biological predictors of outcome...
  26. ncbi request reprint Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1
    Giuseppe Giaccone
    Vrije Universiteit Medical Center, Department of Oncology, De Boelelaan 1117, 1081 Amsterdam, The Netherlands
    J Clin Oncol 22:777-84. 2004
    ..Gefitinib has demonstrated encouraging efficacy in advanced NSCLC in phase II trials in pretreated patients, and a phase I trial of gefitinib in combination with gemcitabine and cisplatin showed favorable tolerability...
  27. ncbi request reprint Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells
    Hans J J van der Vliet
    Department of Medical Oncology, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands
    Cancer Res 63:4101-6. 2003
    ....
  28. pmc Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors
    Johannes Voortman
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:13040-5. 2010
    ..Finally, by analyzing potential drug targets, we provide a genomics-based rationale for targeting the AKT-mTOR and apoptosis pathways in SCLC...
  29. doi request reprint Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells
    Cecilia Ceresa
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Mol Cancer Ther 8:1026-36. 2009
    ..The increase of deoxycytidine kinase and dFdCTP might contribute to this synergistic interaction and supports its further clinical investigation...
  30. doi request reprint Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours
    Hester van Cruijsen
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Eur J Cancer 46:901-11. 2010
    ..Combination treatment with cediranib and gefitinib, an EGFR signalling inhibitor, was evaluated in patients with advanced solid tumours...
  31. doi request reprint Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib
    Elisa Giovannetti
    Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam CCA 1 52, Amsterdam, The Netherlands
    Mol Cancer Ther 9:581-93. 2010
    ....
  32. ncbi request reprint Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export
    Miriam Ferrer
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Hum Mol Genet 14:1271-81. 2005
    ..Taken together, these findings indicate that FANCA can be actively exported out of the nucleus by CRM1, revealing a new mechanism to regulate the function of the FA protein complex...
  33. doi request reprint Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients
    Clara Lemos
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, The Netherlands
    Pharmacogenomics 12:159-70. 2011
    ..The current study investigates whether or not functional polymorphisms in the ATP-binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non-small-cell lung cancer (NSCLC) patients...
  34. pmc A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas
    Arun Rajan
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:6831-9. 2011
    ..To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas...
  35. pmc Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells
    Meng Tzu Weng
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 109:E3659-67. 2012
    ..Together, these findings identify a role of ERH in mRNA splicing and mitosis, and they provide evidence that KRAS mutant cancer cells are dependent on ERH for their survival...
  36. doi request reprint EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection
    Sinchita Roy Chowdhuri
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA
    Mod Pathol 25:548-55. 2012
    ....
  37. pmc Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer
    Victoria L Luchenko
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cell Cycle 10:3119-28. 2011
    ..These results suggest that DNA relaxation is not required for synergy of HDIs with DNA damaging agents, and that scheduling of drug administration will be critical for rational development of clinical protocols...
  38. doi request reprint Histone deacetylase inhibitors in cancer therapy
    Min Jung Lee
    Medical Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland 20892, USA
    Curr Opin Oncol 20:639-49. 2008
    ..The purpose of this review is to provide an overview of recent advances in the development of histone deacetylase inhibitors (HDACi) for the treatment of cancer...
  39. doi request reprint Chemotherapy for thymic tumors: induction, consolidation, palliation
    Arun Rajan
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Thorac Surg Clin 21:107-14, viii. 2011
    ..In this article we outline various clinical trials that have been performed to evaluate the role of chemotherapy in the treatment of thymic malignancies...
  40. ncbi request reprint FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy
    Miriam Ferrer
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Lung Cancer 6:250-4. 2005
    ..In conclusion, the activation status of the FA pathway had no value in predicting sensitivity to platinum-based chemotherapy in patients with advanced NSCLC...
  41. doi request reprint Small-molecule inhibitors of the human epidermal receptor family
    Corey A Carter
    National Cancer Institute, NIH, Bethesda Naval Hospital, Building 10, Room 13N222, Bethesda, MD 20892, USA
    Expert Opin Investig Drugs 18:1829-42. 2009
    ..At present, there are two small-molecule inhibitors (erlotinib and lapatinib) approved by the FDA in the USA, and a third inhibitor, gefitinib, is approved in other countries...
  42. pmc MicroRNA expression and clinical outcome of small cell lung cancer
    Jih Hsiang Lee
    Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 6:e21300. 2011
    ..Our results suggest that the expression of the 7 selected microRNAs are not prognostic in SCLC patients, and miR-34a is unrelated to the malignant behavior of SCLC cells and is unlikely to be a therapeutic target...
  43. pmc 18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors
    Anish Thomas
    Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 19:1487-93. 2013
    ..The primary objective of this study was to assess the usefulness of early [(18)F]-FDG PET to monitor treatment efficacy and its correlation with Response Evaluation Criteria in Solid Tumors (RECIST) in patients with TETs...
  44. pmc Whole genome and transcriptome sequencing of a B3 thymoma
    Iacopo Petrini
    Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    PLoS ONE 8:e60572. 2013
    ....
  45. pmc Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain
    Matheus M de Gunst
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Mol Cancer 6:56. 2007
    ..The phenotypical consequences of different EGFR mutations may vary dramatically, but the majority of uncommon EGFR mutations have never been functionally evaluated...
  46. doi request reprint Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival
    Hester van Cruijsen
    Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 14:5884-92. 2008
    ..We investigated the effect of sunitinib, a tyrosine kinase inhibitor of fms-like tyrosine kinase-3, KIT, and vascular endothelial growth factor receptors, on myeloid differentiation in renal cell cancer (RCC) patients...
  47. pmc Thymic malignancies: from clinical management to targeted therapies
    Ronan J Kelly
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1457, USA
    J Clin Oncol 29:4820-7. 2011
    ..Here we discuss the results of large-scale genomic analyses conducted to date and review the most active chemotherapies and targeted treatments...
  48. ncbi request reprint Genetic heterogeneity in patients with multiple neoplastic lung lesions: a report of three cases
    Marielle I Gallegos Ruiz
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    J Thorac Oncol 2:12-21. 2007
    ..A better understanding of the molecular alterations present in the different lesions may help in defining this relation...
  49. ncbi request reprint Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells
    Linda E Bröker
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Cancer Res 64:27-30. 2004
    ..Interestingly, inhibition of cathepsin B prevents the appearance of multinucleated cells, an early characteristic of MSA-induced cell death, pointing to a central, proximal role for cathepsin B in this novel cell death pathway...
  50. ncbi request reprint Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, 1117 De Boelelaan, Amsterdam, The Netherlands
    J Clin Oncol 23:6854-64. 2005
    ..We assessed whether Bec2/bacille Calmette-Guerin (BCG) vaccination prolongs survival in patients with limited-disease small-cell lung cancer (SCLC) after a major response to chemotherapy and chest radiation...
  51. ncbi request reprint Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC)
    Elisa Giovannetti
    Dept of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Curr Drug Targets 11:12-28. 2010
    ....
  52. ncbi request reprint A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183
    Linda E Bröker
    VU University Medical Center, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Clin Cancer Res 13:3906-12. 2007
    ..Additionally, the pharmacokinetics and possible antitumor activity were studied...
  53. ncbi request reprint Global histone modifications predict prognosis of resected non small-cell lung cancer
    Fabrice Barlesi
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 25:4358-64. 2007
    ..Epigenetic modifications may contribute to the development and progression of cancer. We investigated whether epigenetic changes involving multiple histones influence prognosis of non-small-cell lung cancer (NSCLC) patients...
  54. doi request reprint Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells
    Terry W Moody
    Department of Health and Human Services, National Cancer Institute, Center for Cancer Research, Office of the Director, Bethesda, Maryland 20892, USA
    Eur J Pharmacol 637:38-45. 2010
    ..The results indicate that the NMB receptor regulates EGF receptor transactivation by a mechanism dependent on Src as well as metalloprotease activation and generation of reactive oxygen species...
  55. doi request reprint Treatment of advanced thymoma and thymic carcinoma
    Arun Rajan
    Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA
    Curr Treat Options Oncol 9:277-87. 2008
    ..In recent years, a better understanding of the biologic basis of thymic epithelial tumors has led to the emergence of targeted therapy directed against this malignancy...
  56. pmc Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Eur J Cancer 46:340-7. 2010
    ....
  57. ncbi request reprint EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens
    Marielle I Gallegos Ruiz
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Cell Oncol 29:257-64. 2007
    ..Furthermore, we compare the sensitivity of the analysis using genomic DNA (gDNA) versus RNA...
  58. pmc Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells
    Terry W Moody
    National Cancer Institute, Office of the Director, Center for Cancer Research, Bethesda, MD 20892 1500, USA
    Lung Cancer 68:154-60. 2010
    ..Because S-valproate and S-diclofenac inhibit the growth of NSCLC cells and reduce PGE(2) levels, they may prove beneficial in the chemoprevention and/or therapy of NSCLC...
  59. ncbi request reprint The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients
    Martijn R Meijerink
    Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands
    Eur Radiol 17:1700-13. 2007
    ..In conclusion, CTP is feasible in showing changes of perfusion induced by anti-angiogenic therapy...
  60. doi request reprint Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183
    Linda E Bröker
    VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 14:4186-91. 2008
    ..Pharmacokinetic sampling was done up to 72 hours after the first four doses and analyzed with a validated liquid chromatography/mass spectrometry assay...
  61. ncbi request reprint Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, 1117 De Boelelaan, Amsterdam, The Netherlands
    J Clin Oncol 23:3235-42. 2005
    ....
  62. ncbi request reprint EGFR inhibitors in lung cancer
    Jan Buter
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Oncology (Williston Park) 19:1707-11; discussion 1711-2, 1720-3. 2005
    ..Newer drugs inhibiting more than one receptor pathway are being investigated in order to find activity in a broader group of patients...
  63. ncbi request reprint Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity
    Linda E Bröker
    VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 12:1760-7. 2006
    ..BMS-275183 is an orally administered C-4 methyl carbonate analogue of paclitaxel. We did a dose-escalating phase I study to investigate its safety, tolerability, pharmacokinetics, and possible antitumor activity...
  64. ncbi request reprint Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975
    Egbert F Smit
    Department of Pulmonogy, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 21:3909-17. 2003
    ..Materials and..
  65. doi request reprint Semiautomated laser capture microdissection of lung adenocarcinoma cytology samples
    Sinchita Roy Chowdhuri
    Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
    Acta Cytol 56:622-31. 2012
    ..In the past we have used laser capture microdissection (LCM) to select for pure populations of tumor cells to increase the sensitivity of molecular assays. This study explores several methods for semiautomated computer-guided LCM...
  66. ncbi request reprint Cell death independent of caspases: a review
    Linda E Bröker
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 11:3155-62. 2005
    ..Here we review the various models of PCD and their death pathways at molecular and organelle level and discuss the relevance of the growing knowledge of caspase-independent cell death pathways for cancer...
  67. ncbi request reprint Lung cancer
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Cancer Chemother Biol Response Modif 21:445-83. 2003
  68. ncbi request reprint Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors
    Maarten L Janmaat
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Oncologist 8:576-86. 2003
    ..Of these, small-molecule tyrosine kinase inhibitors represent one of the most promising classes of anticancer agents. Here, we describe the status of small-molecule EGFR tyrosine kinase inhibitors in preclinical and clinical development...
  69. ncbi request reprint Targeting HER1/EGFR in cancer therapy: experience with erlotinib
    Giuseppe Giaccone
    Vrije Universiteit Medical Center, Head of Division of Medical Oncology, 1117 De Boelelaan, Amsterdam, The Netherlands
    Future Oncol 1:449-60. 2005
    ..Erlotinib has demonstrated the clinical activity in a variety of solid tumors, and has recently demonstrated improvements in survival in large Phase III trials, in non-small-cell lung cancer and pancreatic cancer...
  70. ncbi request reprint Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA
    Miriam Ferrer
    Department of Medical Oncology, Division of Gene Therapy, VU University Medical Center, Amsterdam, The Netherlands
    Cancer Gene Ther 11:539-46. 2004
    ....
  71. pmc Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality
    Ronan J Kelly
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Clin Lung Cancer 11:228-37. 2010
    ....
  72. doi request reprint A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies
    Bart Kuenen
    Department of Oncology, Free University Hospital of Amsterdam, Amsterdam, The Netherlands
    Clin Cancer Res 16:1915-23. 2010
    ....
  73. pmc Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report
    Jens Voortman
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    BMC Cancer 6:129. 2006
    ..Nevertheless, acute development or exacerbation of congestive cardiac failure has been associated with bortezomib treatment...
  74. pmc A population-based assessment of mortality and morbidity patterns among patients with thymoma
    Shahinaz M Gadalla
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
    Int J Cancer 128:2688-94. 2011
    ..0, 95% CI = 1.7-4.8). Despite the improved survival for thymoma patients over time, they have worse survival than controls. Thymoma patients are in need for follow-up to detect and manage autoimmune diseases and cancer...
  75. doi request reprint Targeting the dynamic HSP90 complex in cancer
    Jane Trepel
    Medical Oncology Branch Center for Cancer Research, National Cancer Institute, Building 10, Room 1 5940, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Nat Rev Cancer 10:537-49. 2010
    ....
  76. doi request reprint Next generation oncology drug development: opportunities and challenges
    Martin E Gutierrez
    National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Nat Rev Clin Oncol 6:259-65. 2009
    ..We present a review of the opportunities and challenges facing drug development in oncology through the phases of clinical development starting with first-in-human trials...
  77. ncbi request reprint The role of gefitinib in lung cancer treatment
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 10:4233s-4237s. 2004
    ..Additional studies are indicated to assess the possible role of gefitinib in the maintenance of patients who received chemotherapy or chemoradiotherapy. Studies investigating gefitinib as first-line monotherapy are also required...
  78. ncbi request reprint Signal transduction modulators for cancer therapy: from promise to practice?
    Marinus W Lobbezoo
    NDDO Research Foundation, Amsterdam, The Netherlands
    Oncologist 8:210-3. 2003
  79. ncbi request reprint The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer
    Ariel Lopez-Chavez
    National Cancer Institute, Medical Oncology Branch, Center for Cancer Research, Building 10, Room 12N226, 10 Center Drive, Bethesda, MD 20892, USA
    Curr Opin Investig Drugs 10:1305-14. 2009
    ..Several strategies are being developed to overcome this mechanism of resistance, including MEK inhibitors, Braf inhibitors, Hsp90 inhibitors, K-Ras-directed immunotherapy, mTOR inhibitors and several combination approaches...
  80. ncbi request reprint A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus
    Bernard M Tijink
    Department of Otolaryngology Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 12:6064-72. 2006
    ..Bivatuzumab is a humanized monoclonal antibody directed against CD44v6, which previously seemed to be safe in phase I radioimmunotherapy trials, whereas the conjugated mertansine is a potent maytansine derivative...
  81. ncbi request reprint Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)
    Jose Belderbos
    Department of Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Eur J Cancer 43:114-21. 2007
    ..A randomised phase III study was performed comparing sequential (S) and concurrent (C) chemo-radiotherapy (CRT) in non-small cell lung cancer (NSCLC) patients...
  82. doi request reprint Antiangiogenic therapy in nonsmall cell lung cancer
    Martin Gutierrez
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Curr Opin Oncol 20:176-82. 2008
    ..This review summarizes recent findings on targeting mediators of angiogenesis, treatment options and molecular targets in development...
  83. ncbi request reprint Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients
    Maarten L Janmaat
    Department of Medical Oncology, Vreije Universiteit Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 24:1612-9. 2006
    ..Several biologic features were investigated as potential markers of gefitinib activity...
  84. ncbi request reprint STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer
    Yisong Wang
    Center for Cancer Research, Medical Oncology Branch and Urologic Oncology Branch, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Curr Opin Investig Drugs 11:1466-76. 2010
    ..The further development of this agent, and the other Hsp90 inhibitors, may be dependent on the tumor type and the primary oncogenic driving forces...
  85. ncbi request reprint Targeted therapy in non-small cell lung cancer
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, Amsterdam 1081, The Netherlands
    Lung Cancer 38:S29-32. 2002
    ..This "targeted therapy" represents a new generation of anticancer treatment and a chance to revitalize the moribund state of NSCLC treatment...
  86. pmc Plantar erythrodysesthesia with bullous otitis externa, toxicities from sorafenib: a case report
    Corey A Carter
    CCR, National Cancer Institute, 10 Center Drive, Building 10, Room 12N226, Bethesda, MD 20892, USA
    Cases J 2:6264. 2009
    ..Otoscopic exam revealed bilateral external canal bullous lesion. The patient was diagnosed with plantar erythrodysesthesia with bullous otitis externa, a new toxicities in patients being treated with sorafenib...
  87. pmc Acupuncture treatment for persistent hiccups in patients with cancer
    Adeline X Y Ge
    Division of Intramural Research, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD 20892, USA
    J Altern Complement Med 16:811-6. 2010
    ..The objective of this study was to investigate the effects of acupuncture treatment for persistent hiccups in cancer patients...
  88. ncbi request reprint A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, HV 1081 Amsterdam, The Netherlands
    Clin Cancer Res 8:3702-9. 2002
    ..We performed a dose escalation study of KRN7000 in advanced cancer patients...
  89. ncbi request reprint Novel approaches to the treatment of non-small cell lung cancer
    Carlos G Ferreira
    Department of Medical Oncology, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands
    Crit Rev Oncol Hematol 41:57-77. 2002
    ..Finally, perspectives of future applications and impact on the treatment of NSCLC are also discussed...
  90. ncbi request reprint The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors
    Godefridus J Peters
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 10:4072-6. 2004
    ..4:1...
  91. doi request reprint The role of talactoferrin alpha in the treatment of non-small cell lung cancer
    Ronan J Kelly
    National Cancer Institute, Medical Oncology, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 10:1379-86. 2010
    ..Immunotherapeutic approaches to treating NSCLC via either adoptive transfer of immunity or stimulation of the endogenous immune system have shown increasing promise in recent years...
  92. ncbi request reprint Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Semin Oncol 29:47-9. 2002
    ..Further follow-up and analysis of quality of life may clarify this possible difference in treatment outcome...
  93. ncbi request reprint Clinical impact of novel treatment strategies
    Giuseppe Giaccone
    Division of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Oncogene 21:6970-81. 2002
    ..All these novel therapies open a new era of anticancer treatment that will likely complement the currently available therapies in the near future...
  94. ncbi request reprint Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies
    Hester van Cruijsen
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Int J Cancer 117:883-8. 2005
    ..Preliminary efficacy data from clinical trials encourage further exploration of this combined anticancer strategy...
  95. ncbi request reprint Update on the systemic treatment of lung cancer
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, 1117 De Boelelaan, HV 1081 Amsterdam, The Netherlands
    Cancer Chemother Biol Response Modif 20:697-716. 2002
  96. ncbi request reprint Systemic treatment of malignant thymoma: a decade experience at a single institution
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Am J Clin Oncol 29:336-44. 2006
    ..Thymic malignancies are rare tumors on the superior anterior mediastinum. Treatment of advanced stages includes chemotherapy. The objective of this analysis was to review the treatment of this disease in the past decade...
  97. ncbi request reprint A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients
    C Huisman
    Department of Pulmonary, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
    Ann Oncol 12:1567-73. 2001
    ..No objective responses were seen. CONCLUSION: Although the combined use of topoisomerase I and II inhibitors is attractive on theoretical grounds, excessive myelosuppression prevents substantial dose escalation...
  98. pmc DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?
    E Smitskamp-Wilms
    Department of Oncology, Free University Hospital, Amsterdam, The Netherlands
    Br J Cancer 72:917-21. 1995
    ..The degree of variation found for DTD (range 4-250 nmol min-1 mg-1), was not observed for these enzymes (CP450R, 0.8-7.8 nmol cytochrome c min-1 mg-1; Cb5R, 3.5-27.6 nmol min-1 mg-1).(ABSTRACT TRUNCATED AT 250 WORDS)..
  99. ncbi request reprint Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
    G Giaccone
    Division of Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
    J Clin Oncol 16:2133-41. 1998
    ..To compare two cisplatin based chemotherapy schedules in patients with advanced non-small-cell lung cancer (NSCLC)...
  100. pmc Determinants of CPT-11 and SN-38 activities in human lung cancer cells
    J van Ark Otte
    University Hospital Vrije Universiteit, Department of Medical Oncology, Amsterdam, The Netherlands
    Br J Cancer 77:2171-6. 1998
    ..The assessment of CE activity in clinical material of lung cancer patients undergoing treatment with CPT-11 may be warranted. However, other mechanisms may influence sensitivity to CPT-11, possibly including drug transport...
  101. ncbi request reprint Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)
    N Van Zandwijk
    Netherlands Cancer Institute and Free University, Amsterdam, The Netherlands
    J Clin Oncol 18:2658-64. 2000
    ....